Literature DB >> 22526832

Clinical analysis of 50 children with juvenile dermatomyositis.

Takayuki Kishi1, Takako Miyamae, Ryoki Hara, Shoko Nakajima, Tomoyuki Imagawa, Masaaki Mori, Shumpei Yokota.   

Abstract

OBJECTIVE: We performed a retrospective review of medical records to assess the clinical characteristics of 50 Japanese children with juvenile dermatomyositis (JDM).
METHODS: Fourteen boys and 36 girls who visited Yokohama City University Hospital between 1983 and 2008 were enrolled. Gender, age at disease onset and diagnosis, presenting clinical features, laboratory data at onset, complications, treatment, and outcome were reviewed.
RESULTS: Mean age at disease onset was 6.9 years. Clinical manifestations at the first visit were muscle pain and/or weakness (90 %), malar rash (90 %), Gottron's papules (86 %), and heliotrope rash (80.0 %). Elevated serum levels of creatine kinase were found in 57.0 % of patients and aldolase in 95 %. T2-weighted magnetic resonance (MR) images with fat suppression demonstrated positive findings in 89.5 % of patients. Initial treatment was prednisolone (PSL) orally or pulsed methylprednisolone (mPSL) i.v. Pulsed mPSL therapy showed efficacy superior to PSL [flare in 8 of 19 (42 %) vs. 18 of 25 (72 %)]. Children refractory to initial treatment were given additional pulsed mPSL and/or cyclophosphamide (IVCY; n = 19) i.v.. Four patients with interstitial pneumonia responded well to IVCY.
CONCLUSIONS: Our findings support the notion that JDM might be considered as both a systemic inflammatory and noninflammatory vasculopathy best treated by IVCY, as shown in previous literature.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526832     DOI: 10.1007/s10165-012-0647-4

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  8 in total

Review 1.  Use of Rescue Therapy with IVIG or Cyclophosphamide in Juvenile Myositis.

Authors:  Theonymfi Doudouliaki; Charalampia Papadopoulou; Claire T Deakin
Journal:  Curr Rheumatol Rep       Date:  2021-03-08       Impact factor: 4.592

Review 2.  Treatment of Calcinosis in Juvenile Dermatomyositis.

Authors:  Ovgu Kul Cinar; Charalampia Papadopoulou; Clarissa A Pilkington
Journal:  Curr Rheumatol Rep       Date:  2021-02-08       Impact factor: 4.592

3.  Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children.

Authors:  Sulaiman M Al-Mayouf; Nora AlMutiari; Mohammed Muzaffer; Rawiah Shehata; Adel Al-Wahadneh; Reem Abdwani; Safia Al-Abrawi; Mohammed Abu-Shukair; Zeyad El-Habahbeh; Abdullah Alsonbul
Journal:  Rheumatol Int       Date:  2017-07-06       Impact factor: 2.631

4.  Juvenile dermatomyositis: a tertiary center experience.

Authors:  Kenan Barut; Pinar Ozge Avar Aydin; Amra Adrovic; Sezgin Sahin; Ozgur Kasapcopur
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

5.  Clinical course and outcomes of Iranian children with juvenile dermatomyositis and polymyositis.

Authors:  Abdolreza Malek; Seyed-Reza Raeeskarami; Vahid Ziaee; Yahya Aghighi; Mohamad-Hassan Moradinejad
Journal:  Clin Rheumatol       Date:  2014-05-31       Impact factor: 2.980

6.  Clinical characteristics of children with juvenile dermatomyositis: the Childhood Arthritis and Rheumatology Research Alliance Registry.

Authors:  Angela Byun Robinson; Mark F Hoeltzel; Dawn M Wahezi; Mara L Becker; Elizabeth A Kessler; Heinrike Schmeling; Ruy Carrasco; Adam M Huber; Brian M Feldman; Ann M Reed
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-03       Impact factor: 4.794

Review 7.  Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.

Authors:  Lisa G Rider; Katalin Dankó; Frederick W Miller
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

8.  Superimposed Segmental Manifestation of Juvenile Amyopathic Dermatomyositis in a 9-year-old Boy.

Authors:  Isil Bulur; Hilal Kaya Erdogan; Zeynep Nurhan Saracoglu; Rudolf Happle; Funda Canaz
Journal:  Indian J Dermatol       Date:  2017 Jul-Aug       Impact factor: 1.494

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.